- ST Pharm signed an agreement with Multiverse Pharma in the United States for joint research on new antibody-encoding (AER) platform technology and biobetter mRNA drugs.

- Under the agreement, ST Pharm and Multiverse Pharma will develop first-in-class mRNA medicines and biobetter candidates with improved selectivity, stability, and immunogenicity for antibody drugs whose mechanism of action has been identified and whose safety and efficacy were proven through clinical trials.

[News Link]